KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.

Paul G Richardson, Aurore Perrot, Joseph Mikhael, Thomas Martin, Meral Beksac, Ivan Spicka, Marcelo Capra, Mattia D'Agostino, Pieter Sonneveld, Kamlesh Bisht, Taro Fukao, Rick Zhang, Keisuke Tada, Christina Tekle, Sandrine Macé, Zandra Klippel, Helgi van de Velde, Philippe Moreau

Blood Cancer J 14(1) 209

PMID39609425
PMCIDPMC11605113
DOI10.1038/s41408-024-01149-w
发表日期2024-11-28
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

The International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The phase 3 ICARIA-MM (isatuximab-pomalidomide-dexamethasone vs. pomalidomide-dexamethasone) and IKEMA (isatuximab-carfilzomib-dexamethasone vs. carfilzomib-dexamethasone) studies provide large datasets for retrospectively validating the prognostic value of the R2-ISS in relapsed/refractory multiple myeloma. Of 609 pooled patients, 68 (11.2%) were reclassified as R2-ISS stage I, 136 (22.3%) as R2-ISS stage II, 204 (33.5%) as R2-ISS stage III, 55 (9.0%) as stage IV, and 146 (24.0%) "Not classified". Median progression-free survival was shorter among those reclassified as R2-ISS stage II (HR 1.52, 95% CI 0.979-2.358), stage III (HR 2.59, 95% CI 1.709-3.923), and stage IV (HR 3.51, 95% CI 2.124-5.784) versus stage I. Adding isatuximab led to longer progression-free survival versus doublet therapy (adjusted HR 0.544 [95% CI 0.436-0.680]), with a consistent treatment effect observed across all R2-ISS stages. This is the first study to validate the R2-ISS with novel agents, including anti-CD38 monoclonal antibodies, and to show that R2-ISS, as a prognostic scoring system, can be applied to patients with relapsed/refractory multiple myeloma.

KM 提取结果

3 个 Figure · 7 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Fig. 2. Pooled data from ICARIA-MM and IKEMA. A validation curves showing progression-free survival by R2-ISS stage. B hazard ratios of progression-free survival by subgroups with individual risk factors. CI confidence interval, HR hazard ratio, ISS International Staging System, LDH lactate dehydrogenase, NC not calculable, PFS progression-free survival, R2-ISS Second Revision of the International Staging System, ULN upper limit of normal.

A

PFS

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 5 条 已提取 5 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:extreme upward reversal曲线 5:short span
查看结果
KM Figure1 个面板

Fig. 3

Fig. 3. Pooled data from ICARIA-MM and IKEMA. A validation curves showing overall survival by R2-ISS stage. B hazard ratios of overall survival by subgroups with individual risk factors. CI confidence interval, HR hazard ratio, ISS International Staging System, LDH lactate dehydrogenase, NC not calculable, OS overall survival, R2-ISS Second Revision of the International Staging System, ULN upper limit of normal.

A

overall survival

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 5 条 已提取 5 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 5:extreme upward reversal
查看结果
KM Figure5 个面板

Fig. 4

Fig. 4 Progression-free survival (Isa-based triplet vs. doublet), by R2-ISS stage (pooled data from ICARIA-MM and IKEMA based on disease assessment by the independent response committees). CI confidence interval, HR hazard ratio, Isa-Kd isatuximab–carfilzomib–dexamethasone, Isa-Pd isatuximab–pomalidomide–dexamethasone, PFS progression-free survival, R2-ISS Second Revision of the International Staging System.

Stage_I

PFS

Fig. 4 · Panel Stage_I

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Stage_I 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Stage_II

PFS

Fig. 4 · Panel Stage_II

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Stage_II 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Stage_III

PFS

Fig. 4 · Panel Stage_III

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Stage_III 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Stage_IV

PFS

Fig. 4 · Panel Stage_IV

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Stage_IV 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Not_classified

PFS

Fig. 4 · Panel Not_classified

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Not_classified 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Patients from the ICARIA-MM and IKEMA trials included in the present analysis.
非 KM Figure